Combination of mitomycin C and low-dose metronidazole synergistically against <i>Clostridioides difficile</i> infection and recurrence prevention.

ABSTRACT: Clostridioides difficile is an anaerobic, spore-forming pathogen responsible for illnesses ranging from mild diarrhea to life-threatening colitis. Current treatments rely on antibiotics such as vancomycin and metronidazole (MTZ), but high doses can disrupt gut microbiota, contributing to recurrent infections. Mitomycin C (MMC), a Food and Drug Administration-approved anticancer agent, is known to induce prophage activation in lysogenic bacteria. Given that over 70% of C. difficile strains harbor prophages, we evaluated MMC's potential to enhance antibiotic efficacy against C. difficile infection (CDI). In vitro, MMC synergized with MTZ to inhibit strain R20291 and clinical isolates of RT027 and RT078 while reducing the minimum bactericidal concentration of MTZ a

SUBMITTER: Gong J-J 

PROVIDER: S-EPMC12326999 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature